HOB Biotech Shanghai Subsidiary Enrolls First Patient in Clinical Trial for Anti-Allergy Product

marketscreener
2025.09.25 07:15
portai
I'm PortAI, I can summarize articles.

HOB Biotech's Shanghai subsidiary has enrolled its first patient in a phase 3 clinical trial for its MM09 sublingual desensitization spray targeting allergies from house dust mites. The company has also secured import permits for the drug in Hong Kong and Macao for cat and dog hair allergens. Following this news, shares rose by 1% in late afternoon trading on Wednesday.

Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.